Download PDF
Der Klinikarzt 2018; 47(10): 468-471
DOI: 10.1055/a-0737-4283
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Amyotrophe Lateralsklerose

Neue Erkenntnisse und Therapieansätze
Jochen H. Weishaupt
Klinik für Neurologie, Universitätsklinikum Ulm, Ulm
,
Johannes Dorst
Klinik für Neurologie, Universitätsklinikum Ulm, Ulm
,
Albert C. Ludolph
Klinik für Neurologie, Universitätsklinikum Ulm, Ulm
› Author Affiliations
Further Information

Publication History

Publication Date:
31 October 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das Bild der Amyotrophen Lateralsklerose (ALS) hat sich in den vergangenen Jahren durch neue Erkenntnisse im Hinblick auf Phänotyp und Verlauf, Neuropathologie und Genetik deutlich gewandelt. Zudem werden aktuell innovative verlaufsmodifizierende Therapieansätzen sichtbar.

 

  • Literatur

  • 1 Brettschneider J, Del Tredici K, Toledo JB. et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20-38
    CrossrefPubMedGoogle Scholar
  • 2 Weishaupt JH, Hyman T, Dikic I. Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Trends Mol Med 2016; 22: 769-783
    CrossrefPubMedGoogle Scholar
  • 3 Brettschneider J, Del Tredici K, Irwin DJ. et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 2014; 127: 423-439
    CrossrefPubMedGoogle Scholar
  • 4 Feiler MS, Strobel B, Freischmidt A. et al. TDP-43 is intercellularly transmitted across axon terminals. J Cell Biol 2015; 211: 897-911
    CrossrefPubMedGoogle Scholar
  • 5 Ludolph A 1, Drory V, Hardiman O. et al. WFN Research Group On ALS/MND. A revision of the El Escorial criteria – 2015. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16: 291-292
    CrossrefPubMedGoogle Scholar
  • 6 Braak H, Brettschneider J, Ludolph AC. et al. Amyotrophic lateral sclerosis – a model of corticofugal axonal spread. Nat Rev Neurol 2013; 9: 708-714
    CrossrefPubMedGoogle Scholar
  • 7 Rosenbohm A, Liu M, Nagel G. et al. Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol 2018; 265: 774-782
    CrossrefPubMedGoogle Scholar
  • 8 Spencer PS, Palmer VS, Ludolph AC. On the decline and etiology of high-incidence motor system disease in West Papua (southwest New Guinea). Mov Disord 2005; 20 (Suppl. 12) S119-S126
    CrossrefPubMedGoogle Scholar
  • 9 Weydt P, Oeckl P, Huss A. et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 2016; 79: 152-158
    CrossrefPubMedGoogle Scholar
  • 10 Freischmidt A, Müller K, Zondler L. et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain 2014; 137: 2938-2950
    CrossrefPubMedGoogle Scholar
  • 11 Brenner D, Yilmaz R, Müller K. et al. Hot-spot KIF5A mutations cause familial ALS. Brain. 12.01.2018 DOI: doi: 10.1093/brain/awx370 [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 12 Edaravone Writing group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16: 505-512
    CrossrefPubMedGoogle Scholar